Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Lilly

Dow Jones Futures Fall As Target Tumbles; Nvidia Looms Over Stock Market

The Nasdaq hit a new high Tuesday but Target tumbled early Wednesday. Will Nvidia earnings tonight meet lofty hopes?

Investors Business Daily

IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High

Eli Lilly is Tuesday's IBD Stock Of The Day after shares surged into a buy zone, again, on promising test results for a Crohn's treatment.

Investors Business Daily

1 'Strong Buy' Dividend Stock to Buy and Hold

Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review

The stock market rallied this week, with the Nasdaq regaining its 50-day on a semi-dovish Fed, a tame jobs report and a huge Apple buyback.

Investors Business Daily

Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

StockNews.com

Analysts reveal Eli Lilly stock price targets after earnings

Here's what could happen next to Eli Lilly shares.

The Street

IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views

Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Investors Business Daily

Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test

Eli Lilly stock popped Wednesday after the company's weight-loss drug significantly reduced nighttime sleep apnea events.

Investors Business Daily

Shark Tank's Mark Cuban speaks out on weight-loss drugs

A conversation TheStreet engaged in with Cuban about weight-loss drugs shifted from Novo Nordisk's Ozempic to something new from Eli Lilly.

The Street

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Jumps Early Entry As Viking Charges Obesity Space

Eli Lilly stock is Wednesday's IBD Stock Of The Day. Shares are forming a flat base as competition mounts for its weight-loss drug, Zepbound.

Investors Business Daily

Medicare Will Cover Weight-Loss Drugs — For Some. Here's What It Means For Novo, Lilly.

Novo Nordisk and Eli Lilly stocks dipped Thursday after Medicare said it could pay for weight-loss drugs for some members.

Investors Business Daily

Analyst revamps Eli Lilly stock price target on weight loss drug

Here's what could happen to Eli Lilly shares next.

The Street

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly Taps Amazon's Pharmacy To Deliver Meds, Including Weight-Loss Drug Zepbound

Eli Lilly said Wednesday it tapped Amazon.com's pharmacy division to deliver some of its prescription meds, including its weight-loss drug.

Investors Business Daily

Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk

Novo Nordisk said Friday its weight-loss drug gained FDA approval to cut the risk of heart attack and strokes. Novo Nordisk stock dipped.

International Business Times

Highly Awaited Alzheimer's Drug Hit By Delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

Investors Business Daily

Biogen Surges On A Setback For Eli Lilly's Rival Alzheimer's Treatment

Biogen stock jumped Friday after the FDA delayed its approval decision on Eli Lilly's rival Alzheimer's treatment, donanemab.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

‘It feels like we’ve been lobotomised’: the possible sexual consequences of SSRIs

Long-term sexual dysfunction is a side-effect for some patients who take these widely prescribed antidepressants, and can leave sufferers devastated

Investors Business Daily

How The Red-Hot Obesity Space Could Help Eli Lilly Join The 1,000 Club

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

StockNews.com

3 Biotech Stocks Climbing the Ranks to Watch

The biotech industry is thriving on growing applications across sectors from healthcare to agriculture, favorable government funding and policies, and technological breakthroughs. Amid this backdrop, quality biotech stocks UroGen Pharma (URGN), Foghorn Therapeutics (FHTX), and Galapagos (GLPG) might be ideal additions to one’s watchlist. Read on….

Barchart

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

Investors Business Daily

Viking Therapeutics Catapults 121% As Weight-Loss Drug Beats Out Lilly's Zepbound

A weight-loss drug from Viking topped Lilly's Zepbound in a midstage study Tuesday. Viking stock more than doubled, while Lilly shares fell.

Investors Business Daily

Weight-Loss Tizzy: Why Altimmune Surged 23% As Others Tumbled On A New Study

Biotech stocks Madrigal and Altimmune diverged Monday as Wall Street debated the outcome of a weight-loss study in MASH patients.

Investors Business Daily

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

1 … 4 5 6 7

People

Mangeet Kaur BounsMangeet

Margaret Kaczor Andrew

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.